talabostat has been researched along with Carcinoma--Non-Small-Cell-Lung* in 3 studies
1 review(s) available for talabostat and Carcinoma--Non-Small-Cell-Lung
| Article | Year |
|---|---|
Talabostat.
Talabostat mesilate is an orally active, specific inhibitor of dipeptidyl peptidases, including tumor-associated fibroblast activation protein. However, by an independent mechanism, talabostat also stimulates the upregulation of cytokines and chemokines to engender a tumor-specific host immune response, thus giving it a unique dual mechanism of action. In clinical trials, talabostat has demonstrated significant activity, including achieving complete responses in patients with non-small-cell lung cancer and malignant melanoma. Topics: Animals; Antineoplastic Agents; Boronic Acids; Carcinoma, Non-Small-Cell Lung; Dipeptides; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Drugs, Investigational; Enzyme Inhibitors; Humans; Melanoma; Pyrrolidines | 2007 |
1 trial(s) available for talabostat and Carcinoma--Non-Small-Cell-Lung
| Article | Year |
|---|---|
Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer.
Currently available therapies do improve survival in advanced stage non-small cell lung cancer (NSCLC), but only to a limited degree. Talabostat mesilate (PT-100) is an orally available amino boronic dipeptide that specifically inhibits dipeptidyl peptidases (including fibroblast activation protein) and enhances an immune response. The aim of this study was to determine the efficacy and safety of talabostat in NSCLC patients.. A phase II trial was conducted to evaluate talabostat in combination with docetaxel in patients with advanced NSCLC after failure of previous platinum-based chemotherapy. In total, 42 patients were enrolled.. Talabostat was well tolerated. Two patients achieved a partial response and one achieved a complete response.. There was no evidence that talabostat enhanced the clinical activity of docetaxel in patients with NSCLC. Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Carcinoma, Non-Small-Cell Lung; Dipeptides; Docetaxel; Humans; Lung Neoplasms; Middle Aged; Taxoids | 2009 |
1 other study(ies) available for talabostat and Carcinoma--Non-Small-Cell-Lung
| Article | Year |
|---|---|
Molecule of the month. Talabostat.
Topics: Administration, Oral; Boronic Acids; Carcinoma, Non-Small-Cell Lung; Dipeptides; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Enzyme Inhibitors; Humans; Lung Neoplasms; Molecular Structure; Pyrrolidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2006 |